CD4+ T-cell receptor specific for carrier-protein peptide–MHC class II complexes (CD4+ TCR:pMHCII)

CD4+ T-cell receptors (TCRs) specific for carrier-protein peptide–MHC class II complexes are specialized heterodimeric surface proteins that mediate the recognition of exogenous antigens by helper T cells (Janeway et al., 2001). These receptors recognize a composite surface formed by a peptide fragment, derived from a carrier protein like CRM197 or tetanus toxoid, nestled within the groove of a Major Histocompatibility Complex (MHC) class II molecule (Pollard et al., 2009). This interaction is fundamental to the efficacy of conjugate vaccines, where the carrier protein provides the T-cell epitopes necessary to stimulate B-cell maturation, isotype switching, and immunological memory (Avci et al., 2011). Upon binding, the TCR triggers a signaling cascade involving the CD3 complex and various tyrosine kinases, leading to the secretion of cytokines and the expression of co-stimulatory molecules (Smith-Garvin et al., 2009). In clinical practice, this target is modulated by immunosuppressive drugs like cyclosporine, which inhibits downstream signaling, or biologics like abatacept that interfere with the co-stimulatory signals required for full T-cell activation (Vinci et al., 2012). Dysregulation of these TCR-mediated interactions is a primary driver in autoimmune diseases, where TCRs mistakenly recognize self-peptides presented on MHC II (Nepom, 2002).

Other names

MHC class II-restricted T-cell receptorCarrier-specific T-cell receptorCD4+ TCRAntigen-specific T-cell receptorPeptide-MHC class II-specific TCR

The T-cell receptor (TCR) complex recognizes and binds to a specific peptide-MHC class II complex on an antigen-presenting cell, which initiates an intracellular signaling cascade via the CD3 complex and ZAP-70 kinase, leading to T-cell proliferation, differentiation, and effector cytokine release.